Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343.

Hinner MJ, Aiba RSB, Jaquin TJ, Berger S, Dürr MC, Schlosser C, Allersdorfer A, Wiedenmann A, Matschiner G, Schüler J, Moebius U, Rothe C, Matis L, Olwill SA.

Clin Cancer Res. 2019 Oct 1;25(19):5878-5889. doi: 10.1158/1078-0432.CCR-18-3654. Epub 2019 May 28.

PMID:
31138587
2.

Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey.

Hohlbaum AM, Gille H, Trentmann S, Kolodziejczyk M, Rattenstetter B, Laarakkers CM, Katzmann G, Christian HJ, Andersen N, Allersdorfer A, Olwill SA, Meibohm B, Audoly LP, Swinkels DW, van Swelm RPL.

Br J Pharmacol. 2018 Apr;175(7):1054-1065. doi: 10.1111/bph.14143. Epub 2018 Feb 23.

3.

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016.

Adusumilli PS, Cha E, Cornfeld M, Davis T, Diab A, Dubensky TW Jr, Evans E, Grogan JL, Irving BA, Leidner RS, Olwill SA, Soon-Shiong P, Triebel F, Tuck D, Bot A, Dansey RD, Drake CG, Freeman GJ, Ibrahim R, Patel S, Chen DS.

J Immunother Cancer. 2017 Jun 20;5:50. doi: 10.1186/s40425-017-0253-2. eCollection 2017. Review.

4.

In vivo visualization of MET tumor expression and anticalin biodistribution with the MET-specific anticalin 89Zr-PRS-110 PET tracer.

Terwisscha van Scheltinga AG, Lub-de Hooge MN, Hinner MJ, Verheijen RB, Allersdorfer A, Hülsmeyer M, Nagengast WB, Schröder CP, Kosterink JG, de Vries EG, Audoly L, Olwill SA.

J Nucl Med. 2014 Apr;55(4):665-71. doi: 10.2967/jnumed.113.124941. Epub 2014 Mar 10.

5.

A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity.

Olwill SA, Joffroy C, Gille H, Vigna E, Matschiner G, Allersdorfer A, Lunde BM, Jaworski J, Burrows JF, Chiriaco C, Christian HJ, Hülsmeyer M, Trentmann S, Jensen K, Hohlbaum AM, Audoly L.

Mol Cancer Ther. 2013 Nov;12(11):2459-71. doi: 10.1158/1535-7163.MCT-13-0318. Epub 2013 Sep 3.

6.

Antibody targeting of Cathepsin S induces antibody-dependent cellular cytotoxicity.

Kwok HF, Buick RJ, Kuehn D, Gormley JA, Doherty D, Jaquin TJ, McClurg A, Ward C, Byrne T, Jaworski J, Leung KL, Snoddy P, McAnally C, Burden RE, Gray B, Lowry J, Sermadiras I, Gruszka N, Courtenay-Luck N, Kissenpfennig A, Scott CJ, Johnston JA, Olwill SA.

Mol Cancer. 2011 Dec 14;10:147. doi: 10.1186/1476-4598-10-147.

7.

The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study.

Gormley JA, Hegarty SM, O'Grady A, Stevenson MR, Burden RE, Barrett HL, Scott CJ, Johnston JA, Wilson RH, Kay EW, Johnston PG, Olwill SA.

Br J Cancer. 2011 Nov 8;105(10):1487-94. doi: 10.1038/bjc.2011.408. Epub 2011 Oct 11.

8.

Inhibition of Cathepsin S by Fsn0503 enhances the efficacy of chemotherapy in colorectal carcinomas.

Burden RE, Gormley JA, Kuehn D, Ward C, Kwok HF, Gazdoiu M, McClurg A, Jaquin TJ, Johnston JA, Scott CJ, Olwill SA.

Biochimie. 2012 Feb;94(2):487-93. doi: 10.1016/j.biochi.2011.08.017. Epub 2011 Aug 31.

PMID:
21896304
9.

Application of the Enfer chemiluminescent multiplex ELISA system for the detection of Mycobacterium bovis infection in goats.

Shuralev E, Quinn P, Doyle M, Duignan A, Kwok HF, Bezos J, Olwill SA, Gormley E, Aranaz A, Good M, Davis WC, Clarke J, Whelan C.

Vet Microbiol. 2012 Jan 27;154(3-4):292-7. doi: 10.1016/j.vetmic.2011.07.028. Epub 2011 Aug 4.

PMID:
21862242
10.

Stable expression and purification of a functional processed Fab' fragment from a single nascent polypeptide in CHO cells expressing the mCAT-1 retroviral receptor.

Camper N, Byrne T, Burden RE, Lowry J, Gray B, Johnston JA, Migaud ME, Olwill SA, Buick RJ, Scott CJ.

J Immunol Methods. 2011 Sep 30;372(1-2):30-41. doi: 10.1016/j.jim.2011.06.029. Epub 2011 Jul 19.

PMID:
21782818
11.

Antibody targeting of cathepsin S inhibits angiogenesis and synergistically enhances anti-VEGF.

Ward C, Kuehn D, Burden RE, Gormley JA, Jaquin TJ, Gazdoiu M, Small D, Bicknell R, Johnston JA, Scott CJ, Olwill SA.

PLoS One. 2010 Sep 2;5(9). pii: e12543. doi: 10.1371/journal.pone.0012543.

12.

Expression and purification of diagnostically sensitive mycobacterial (Mycobacterium bovis) antigens and profiling of their humoral immune response in a rabbit model.

Kwok HF, Scott CJ, Snoddy P, Buick RJ, Johnston JA, Olwill SA.

Res Vet Sci. 2010 Aug;89(1):41-7. doi: 10.1016/j.rvsc.2009.12.015. Epub 2010 Jan 22.

PMID:
20096429
13.

Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis.

Burden RE, Gormley JA, Jaquin TJ, Small DM, Quinn DJ, Hegarty SM, Ward C, Walker B, Johnston JA, Olwill SA, Scott CJ.

Clin Cancer Res. 2009 Oct 1;15(19):6042-51. doi: 10.1158/1078-0432.CCR-09-1262. Epub 2009 Sep 29.

14.

A Novel High-Throughput Technique for Identifying Monoclonal Antibodies Capable of Death Receptor Induced Apoptosis.

Kwok HF, Gormley JA, Scott CJ, Johnston JA, Olwill SA.

J Cell Death. 2009 Dec 2;2:45-51. eCollection 2009.

15.

Multiplex immunoassay for serological diagnosis of Mycobacterium bovis infection in cattle.

Whelan C, Shuralev E, O'Keeffe G, Hyland P, Kwok HF, Snoddy P, O'Brien A, Connolly M, Quinn P, Groll M, Watterson T, Call S, Kenny K, Duignan A, Hamilton MJ, Buddle BM, Johnston JA, Davis WC, Olwill SA, Clarke J.

Clin Vaccine Immunol. 2008 Dec;15(12):1834-8. doi: 10.1128/CVI.00238-08. Epub 2008 Oct 15.

16.

Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells.

McCarron PA, Marouf WM, Quinn DJ, Fay F, Burden RE, Olwill SA, Scott CJ.

Bioconjug Chem. 2008 Aug;19(8):1561-9. doi: 10.1021/bc800057g. Epub 2008 Jul 16.

PMID:
18627195
17.

Antibody conjugates and therapeutic strategies.

McCarron PA, Olwill SA, Marouf WM, Buick RJ, Walker B, Scott CJ.

Mol Interv. 2005 Dec;5(6):368-80. Review.

PMID:
16394252
18.

All-trans retinoic acid-induced downregulation of annexin II expression in myeloid leukaemia cell lines is not confined to acute promyelocytic leukaemia.

Olwill SA, McGlynn H, Gilmore WS, Alexander HD.

Br J Haematol. 2005 Oct;131(2):258-64. Erratum in: Br J Haematol. 2006 Jan;132(1):119.

PMID:
16197459
19.

Annexin II cell surface and mRNA expression in human acute myeloid leukaemia cell lines.

Olwill SA, McGlynn H, Gilmore WS, Alexander HD.

Thromb Res. 2005;115(1-2):109-14.

PMID:
15567461

Supplemental Content

Loading ...
Support Center